CAS 171500-79-1

General Information

Dalbavancin is a novel second-generation lipoglycopeptide antibiotic used to treat acute bacterial skin and skin structure infections caused or suspected to be caused by certain types of bacteria. It belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA). Dalbavancin is a semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin.It is derived from a complex of glycopeptide antibiotics, referred to as A-40926, that is produced by a new strain of Actinomadura.

It possesses in vitro activity against a variety of Gram-positive pathogens including MRSA and methicillin-resistant Staphylococcus epidermidis (MRSE).

About the API

Systematic name Dalbavancin B0 5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl- 19-deoxy-56-O-[2-deoxy-2-[(10-methylundecanoyl)amino]-β-D-glucopyranuronosyl]-38-[[3-(dimethylamino)propyl]carbamoyl]-42-O-α-D-mannopyranosyl-15-N-methyl(ristomycin A aglycone) hydrochloride Dalvance, Xydalba
Molecular Formula C88H100Cl2N10O28
Molecular Weight 1816.7
Therapeutic category Infectious disease
Available formulations Injectables